Results 91 to 100 of about 142 (121)
Rezafungin: an opportunity to personalize the treatment of patients with candidemia
Critical CareHonoré, Patrick +2 more
openaire +3 more sources
Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report
JAC-Antimicrobial ResistanceMori, Giovanni +4 more
openaire +3 more sources
Antifungal activity of rezafungin in invasive candidiasis: From bench to bed
Revista Iberoamericana de MicologíaGuillermo Quindós +3 more
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Rezafungin: A Novel Antifungal for the Treatment of Invasive Candidiasis
Future Microbiology, 2021Rezafungin is a novel echinocandin with exceptional stability and solubility and a uniquely long half-life allowing for front-loaded drug exposure with once-weekly dosing. Rezafungin has been shown comparable to other echinocandins, with activity against Candida spp. and Aspergillus spp.
George Thompson, James Lewis
exaly +3 more sources
Expert Opinion on Drug Metabolism and Toxicology
Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on ...
Jason Roberts +2 more
exaly +6 more sources
Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on ...
Jason Roberts +2 more
exaly +6 more sources
Early use of the novel antifungal rezafungin: a case series and literature review
Journal of Antimicrobial ChemotherapyAbstract Objectives Rezafungin is a novel echinocandin with a unique structural configuration enabling weekly IV dosing. We report on early use of rezafungin in our outpatient parenteral antibiotic therapy (OPAT) service, reviewing indications, treatment regimens, outcomes and adverse events in adult ...
Tihana Bicanic, Harriet Davidson
exaly +3 more sources
Formulary Drug Review: Rezafungin
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Brittney Kessel, Danial E. Baker
openaire +2 more sources
Drugs, 2023
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Rezafungin: A Review in Invasive Candidiasis
DrugsRezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration. It has recently been approved for the treatment of adults with invasive candidiasis in the EU and UK, and is approved for adults ...
Simon Fung, Matt Shirley
openaire +2 more sources
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyAbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Benjamin A. August +1 more
openaire +2 more sources